Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|November 23, 2020
Pharmacokinetics under the COVID-19 stormVenkatesh Pilla Reddy, Eman El-Khateeb, Heeseung Jo, et al.
British Journal of Clinical Pharmacology|February 15, 2022
Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategyBuyun Chen, Diansong Zhou, Hua Wei, et al.
British Journal of Clinical Pharmacology|September 24, 2016
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trialsSven Mensing, Doerthe Eckert, Shringi Sharma, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2021
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitorsVenkatesh Pilla Reddy, Adrian J Fretland, Diansong Zhou, et al.
British Journal of Haematology|February 22, 2017
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosisSrdan Verstovsek, Michael R Savona, Ruben A Mesa, et al.
Inflammatory Bowel Diseases|February 28, 2015
Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 studyShringi Sharma, Doerthe Eckert, Jeffrey S Hyams, et al.
American Journal of Obstetrics and Gynecology|September 13, 2012
Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestationSteve N Caritis, Shringi Sharma, Raman Venkataramanan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 7, 2012
Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytesShringi Sharma, Ewa C S Ellis, Roberto Gramignoli, et al.
British Journal of Clinical Pharmacology|September 17, 2021
Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignanciesHelena Edlund, Núria Buil-Bruna, Karthick Vishwanathan, et al.
British Journal of Clinical Pharmacology|April 25, 2022
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjectsShringi Sharma, Xavier Pepin, Jean Cheung, et al.
Pageof 4